Igan

May 14, 2020

Calliditas Therapeutics: Interim Report Q1, 2020

Apr 01, 2020

Calliditas Strengthens its US Commercial Organization

Mar 05, 2020

Data on Acthar® Gel (Repository Corticotropin Injection) Therapy in Immunoglobulin A Nephropathy (IgAN) Published in Kidney International Reports

Jan 22, 2020

Positive Opinion Received From EMA Paediatric Committee on the Paediatric Investigation Plan for Nefecon for the Treatment of IgAN

Dec 23, 2019

The pivotal Phase 3 Clinical Trial NefIgArd Part A Fully Recruited

Oct 01, 2019

Positive Interactions With EMA Provide Route to Conditional Marketing Authorization of Lead Candidate Nefecon

Sep 03, 2019

Positive Feedback From FDA Significantly Benefits Ongoing NefIgArd Pivotal Phase 3 Study

Aug 16, 2019

IgA Nephropathy Patients Invited to Speak About their Disease to the FDA

Jan 14, 2019

Calliditas Therapeutics Appoints Frank Bringstrup as VP Regulatory Affairs

Jan 08, 2019

Calliditas Therapeutics Appoints Andrew Udell to VP Commercial, North America

Nov 13, 2018

First patient Enrolled in Pivotal Clinical Phase 3 Study NEFIGARD with Lead Candidate Nefecon

Oct 01, 2018

Presentation at International IgA Nephropathy Network Meeting Highlighting Supportive Post-hoc Analysis of the NEFIGAN Study